Effectiveness of Intrauterine Levonorgesterel-Releasing Device in the Treatment of Endometrial Hyperplasia in Obese Patients

Basit Öğe Kaydı
dc.contributor.authorTatar, Sezin Ateş
dc.contributor.authorCicekdagi, Isil
dc.date.accessioned2026-01-24T12:00:51Z
dc.date.available2026-01-24T12:00:51Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractAim: Endometrial hyperplasia (EH) is a precursor lesion of endometrial adenocarcinoma, the most common gynecological malignancy in women. Endometrial hyperplasias divided in two groups: non-atypical hyperplasia and atypical hyperplasia. The most commonly used treatment approach is progestin therapy for non-atypical hyperplasias. In this study, we aimed to compare the regression outcomes in control biopsies between obese and non obese patients diagnosed with non-atypical endometrial hyperplasia who were treated with an LNG-IUD and followed up in our clinic. Methods: This study conducted was patients were diagnosed with non-atypical endometrial hyperplasia via endometrial biopsy and treated with intrauterine levonorgestrel. Patient data were reviewed retrospectively. Patients were divided into two groups based on BMI: obese and non-obese. İn regression and treatment success were assessed between control endometrial biopsies taken at 6 and 12 months in the obese and non-obese groups. Results: A total of 110 patients were included in the study who were categorized into two groups according to BMI as obese and non-obese. Data of 32 patients in the obese patient group and 78 patients in the non-obese patient group were examined. In obese patients, the regression rate at the 6th month was 62.5%, and the regression rate at the 12th month was 90.6%. In non-obese patients, the regression rate at the 6th month was 96%, and the regression rate at the 12th month was 97.4%. In the obese patient group, both the 6th-month regression rate and the 12th-month regression rate were statistically significantly lower compared to the non-obese patient group. (p < 0.05). Conclusions: Obesity negatively affects the response to progesterone treatment and that regression rates decrease as BMI increases.
dc.identifier.doi10.30565/medalanya.1575810
dc.identifier.endpage41
dc.identifier.issn2587-0319
dc.identifier.issue1
dc.identifier.startpage36
dc.identifier.trdizinid1308025
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1308025
dc.identifier.urihttps://doi.org/10.30565/medalanya.1575810
dc.identifier.urihttps://hdl.handle.net/20.500.12868/3759
dc.identifier.volume9
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofActa Medica Alanya
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260121
dc.subjectObesity
dc.subjectProgestin
dc.subjectEndometrial hyperplasia
dc.subjectLevo-norgestrel
dc.titleEffectiveness of Intrauterine Levonorgesterel-Releasing Device in the Treatment of Endometrial Hyperplasia in Obese Patients
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Acta Medica Alanya Koleksiyonu